A Phase 3 interventional study of Adalimumab and Methotrexate in Active Rheumatoid Arthritis, sponsored by Cinnagen. Completed at 10 sites in Iran, Islamic Republic of. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-02-02.
Sponsored by Cinnagen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 49th largest by enrollment, is one of 8 that started in 2015, is one of 36 in phase 3, and was the 76th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Medical Center Groningen · Sites in Netherlands
Ages 18+
Qilu Hospital of Shandong University · Sites in China
Ages 18–80
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 12 · Phase 3 39 · Phase 4 33
First in 2000; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 136 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 160 across the 87 interventional studies. Of the 73 that completed or were terminated, 43 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 87 have an industry lead sponsor. The 10 most frequent:
Cinnagen is the lead sponsor of 21 studies on the registry; 1 is open to participants now.
Cinnagen has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and safety of adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active Rheumatoid Arthritis. Patients with the diagnosis of active Rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years will be included. This study is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active-controlled non-inferiority clinical trial. The eligible patients are randomized in a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.
The primary objective of the study is to compare the efficacy of test- adalimumab (CinnoRA®) and the reference adalimumab (Humira®) in patients with moderately to severely active rheumatoid arthritis regarding the evaluation of EULAR criteria based on Disease activity score (DAS).
The secondary objectives of this study are:
The purpose of this study is to compare the efficacy and safety of Adalimumab produced by CinnaGen company and AbbVie adalimumab in subjects with active rheumatoid arthritis. Patients with the diagnosis of active rheumatoid arthritis according to EULAR criteria (European League Against Rheumatism) aged between 18 to 75 years will be included. This study is a Phase III, randomized, two arms, double-blind (patient and assessor blinded), parallel active-controlled non-inferiority clinical trial. The eligible patients will be randomized in a 1:1 ratio to receive CinnoRA® or Humira®. Every two weeks, 40 mg of either of the drugs will be administered to each patient subcutaneously along with methotrexate (15 mg/week), folic acid (1 mg/day), and prednisolone (7.5 mg/day) over six months.
Physical examinations, vital signs, disease activity, and laboratory parameters will be evaluated for patients at baseline and 3 and 6-month visits. The incidence of adverse events at each visit will be recorded based on patients' reports, vital signs, physical examinations, and laboratory tests.
The trial is reviewed by food and drug administration of Iran. The protocol, case report form (CRF), information for patients, and informed consent form are submitted to the ethics committees responsible for review and approval purposes, according to national regulatory guidelines.
In this study, no patient will be recruited without an informed consent form. All the informed consent forms which will be signed by the patients will have two copies so that patients can receive a copy of it.
Determination of sample size:
The outcome measures of this study are changes in composite scores defined by the European League against Rheumatism (EULAR) and the American College of Rheumatology criterions. The CinnoRA® group proportion is assumed to be 0.7100 under the null hypothesis of inferiority. If the response rate of CinnoRA® is at most 18% worse than Humira® (δ = -0.18) (non-inferiority margin), it will be considered to be non-inferior. Sample size 64 in both Humira and CinnoRA® groups yields 90% power to detect non-inferiority margin. The significance level of the test is targeted at 0.0250 (The significance level actually achieved by this design is 0.0284).
DATA QUALITY ASSURANCE:
CinnaGen Company conducts clinical trials according to procedures that incorporate the ethical principles of good clinical practice (GCP). Accurate and reliable data collection is assured by verification and cross-check of the CRFs against the patient's records by clinical monitors, and the maintenance of a drug-dispensing log by the center.
Principle and coordinating investigators, contract research organization (CRO) coordinators and sponsor personnel attend the investigator meetings, and at the end, they receive a GCP certificate.
CRO coordinators and one sponsor attend the Site Initiation Visit (SIV) meetings. Protocol and GCP principles are reviewed by coordinating investigator of each site, and also the needed information for completing CRF and Trial Master File (TMF) forms are explained.
Monitoring by CRO will be performed in 30% and 70% of study progress and at the end of the study. In the monitoring sessions, some sponsor personnel will audit the process. During the monitoring process, the CRO coordinator will check all CRFs and will confirm them to the source documents, and for required cases, the query form will be filled out.
The temperature of the refrigerator which containing the medicines will be checked and recorded by a data logger which will be checked repeatedly by an auditor.
TMF will be checked by CRO coordinator, and it will be rechecked by an auditor. Drug accountability data and information about the proper time for patients' injections will be checked by CRO coordinator and rechecked by sponsor personnel.
After monitoring, problems will be reported by monitor and auditor to the trial centers.
Blinding:
The study will be double-blind. The Subjects and those who conduct the study will be unaware of the state of the patient with regard to the treatment assignments. For this purpose, subjects will be blinded by using a prefilled syringe of Adalimumab, which is quite similar to each other. The injection method, injection syringes, and cartridges are totally the same in both groups. To blind those who conduct the study, the person who delivers or checks the study drug will be different from those who examine the patients. All drugs packages will be identified by unique numbers (manufacture code). Finally, the randomization table will be concealed from research staff by using opaque sealed envelopes.
It should be noted that CRO personnel who enter data into CRF and database and also the sponsor personnel who monitor data entry will be blinded. The study will be double-blind, and situations that might warrant breaking the code are defined in the protocol and include serious adverse events.
Handling of Dropouts or Missing Data:
Since the number of patients who will participate in this clinical trial is limited and small, the investigator can't perform missing imputation analysis and do statistical analysis on those patients who are completed the entire study. However, analyses of the adverse events will be performed on patients who entered the study.
In this study, patients with at least one adverse event will be included in the report. For each adverse event, data will be summarized using frequencies and percentages and then classifies according to the body system. They will be reported in the form of incidence rate. In other words, patients with any number of Adverse Events will be counted only once in this calculation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Have any of the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CinnoRA® (adalimumab Prefilled Syringe produced by CinnaGen Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
Drug: Adalimumab · Drug: Methotrexate · Drug: Folic Acid · Drug: Prednisolone
Humira® (adalimumab Prefilled Syringe produced by AbbVie Company) 40 mg/0.8 ml Every other week 40 mg Adalimumab, will be subcutaneously administered to rheumatic patients during six months. Along with, 15 mg weekly methotrexate, at least 1 mg daily Folic acid and 7.5 mg daily Prednisolone over six months.
Drug: Adalimumab · Drug: Methotrexate · Drug: Folic Acid · Drug: Prednisolone
40 mg Adalimumab every other week is administered subcutaneously to all the patients.
15 mg Methotrexate is weekly administered to all the patients.
At least 1 mg Folic acid is daily administered to all the patients.
7.5 mg Prednisolone is daily administered to all the patients.
Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24
The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula: DAS28-ESR= (0.56\*√(Tender Joint Count)+0.28\*√(Swollen Joint Count)+0.7\*ln(ESR)+0.014\*(global health))
Time frame: Week 24
Percentage of Patients Achieving ACR20, ACR50 and ACR70 Response Rates at Week 24
ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.
Time frame: Week 24
Health Assessment Questionnaire (HAQ) Disability Index at Week 24.
Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.
Time frame: Week 24
The Incidence of Adverse Events
The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.
Time frame: From the time of first treatment up to the last dose of study treatment; 24 weeks.
Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA)
Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.
Time frame: Week 24
| Milestone | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Started | 68 | 68 |
| Completed | 64 | 64 |
| Not completed | 4 | 4 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Positive ppd | 1 | 0 |
| Withdrew: Poor compliance | 1 | 1 |
The primary variables are the percentage of patients with DAS28-EULAR Good and Moderate Responses at week 24 compared with Humira. Moderate response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is equal to or more than 3.2 or decrement of 0.6-1.2 while patient's DAS score is equal to or below 5.1. Good response is defined as decrement of more than 1.2 in patient's DAS score while patient's DAS score is below 3.2. We used the Disease Activity Score-28 for rheumatoid arthritis with erythrocyte sedimentation rate (DAS28-ESR) to assess disease activity in patients with rheumatoid arthritis. This score ranges from 2 to 10, and higher values indicate higher disease activity. DAS28-ESR is calculated with the following formula: DAS28-ESR= (0.56\*√(Tender Joint Count)+0.28\*√(Swollen Joint Count)+0.7\*ln(ESR)+0.014\*(global health))
| percentage of participants | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Percentage of Patients With DAS28-EULAR Good and Moderate Responses at Week 24 | 63 | 63 |
ACR20, ACR50, and ACR70 Response Rates are considered as respectively an Improvement of at Least 20%, 50%, or 70% in American College of Rheumatology (ACR) Score from Baseline at Week 24.
| percentage of participants | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Percentage of Patients achieving ACR20 | 92 | 89 |
| Percentage of Patients achieving ACR50 | 77 | 75 |
| Percentage of Patients achieving ACR70 | 47 | 53 |
Quality of life is assessed using the Health Assessment Questionnaire (HAQ). The HAQ is a self-reported scale used in studies of rheumatoid arthritis to assess areas such as dressing/grooming, arising, eating, walking, reach, grip, maintaining hygiene, and daily activities. There are 20 questions in the mentioned 8 sections. In each section, the highest score is considered as the main answer. Scores should be between 0 and 3 and the final answer is the average of scores relating to all sections. An increased score indicates a worsening of the disability. The disability index of Health Assessment Questionnaire (HAQ) at week 24 is reported.
| score on a scale | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Health Assessment Questionnaire (HAQ) Disability Index at Week 24. | 0.25 (0 to 0.63) | 0.19 (0 to 0.63) |
The incidence of adverse events at each visit is recorded based on patients' reports, vital signs, physical examinations, and laboratory tests for systemic safety, including liver function, renal function, complete blood count and clinical chemistries, urinalysis, and hematologic testing.
| Participants | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| The Incidence of Adverse Events | 23 | 30 |
Number of Participants with Anti-Drug Antibodies (ADA) at Week 24. The ELISA method was used for immunogenicity assessments of adalimumab.
| Participants | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Immunogenicity: Number of Participants With Anti-Drug Antibodies (ADA) | 5 | 2 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| CinnaGen Adalimumab | 1/68 (1.5%) | 2/68 (2.9%) | 23/68 (33.8%) |
| AbbVie Adalimumab | 0/68 (0%) | 1/68 (1.5%) | 30/68 (44.1%) |
| Event | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Peritoneal tuberculosisInfections and infestations | 1/68 | 0/68 |
| PneumoniaInfections and infestations | 1/68 | 1/68 |
| Event | CinnaGen Adalimumab | AbbVie Adalimumab |
|---|---|---|
| Injection site reactionGeneral disorders | 6/68 | 12/68 |
| Respiratory infectionInfections and infestations | 2/68 | 7/68 |
| SinusitisInfections and infestations | 1/68 | 4/68 |
| Flu-like symptomsGeneral disorders | 3/68 | 4/68 |
| NauseaGastrointestinal disorders | 4/68 | 2/68 |
| HeadacheNervous system disorders | 4/68 | 4/68 |
| RashSkin and subcutaneous tissue disorders | 2/68 | 3/68 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/68 | 3/68 |
| UrticariaSkin and subcutaneous tissue disorders | 0/68 | 2/68 |
| Abdominal painGastrointestinal disorders | 2/68 | 1/68 |
| Age, Categorical(Participants) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 59 | 63 | 122 |
| >=65 years | 9 | 5 | 14 |
| Age, Continuous(years) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Mean | 48.29 ± 12.72 | 47.59 ± 11.48 | 47.94 ± 12.08 |
| Sex: Female, Male(Participants) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Female | 58 | 60 | 118 |
| Male | 10 | 8 | 18 |
| Region of Enrollment(Participants) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Iran | 68 | 68 | 136 |
| Patient assessment of pain(units on a scale) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Mean | 67.21 ± 23.51 | 70.22 ± 21.93 | 68.71 ± 22.70 |
| Physician's global assessment of disease activity(units on a scale) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Mean | 68.97 ± 17.38 | 70.44 ± 17.68 | 69.71 ± 17.48 |
| Patient global assessment of disease activity(units on a scale) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Mean | 70.15 ± 20.35 | 70.74 ± 22.21 | 70.44 ± 21.23 |
| Swollen joint count, 28 joints(Swollen joints) | CinnaGen Adalimumab | AbbVie Adalimumab | Total |
|---|---|---|---|
| Mean | 9.96 ± 7.39 | 9.46 ± 6.98 | 9.71 ± 7.17 |
5 further baseline measures are reported on the registry.
Plan to share: No
Ran from Nov 2015 to primary completion in Aug 2016, 8 months.
Results were first posted in Feb 2021, 4 years 5 months after primary completion.
Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 8 months is below that.
Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Adalimumab
Cinnagen